Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 03, 2020
The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to
The RSUs will vest over four years, with 25% of the total number of RSUs vesting on each of the first, second, third and fourth anniversaries of the grant date,
The Company granted the stock options and RSUs as inducement materials to the new employees entering into employment with
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements pertaining to continued service of employees and future vesting of inducement grants. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading “Risk Factors” included in our most recent Form 10-Q filing and in other future filings with the
Dicerna™ and GalXC™ are trademarks of
Amy Trevvett, Dicerna Pharmaceuticals, Inc.
Alex Van Rees, SmithSolve
+1 973-442-1555 ext. 111
Lauren Stival, Stern Investor Relations, Inc.